Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy?

RT @DrSeeboth: Then it is better to go for modern gene therapy and modify #BRCA genes than to subject millions of women to an prophylactic…

RT @LguzzardiM: UK Researchers explore why unaffected female #BRCA2 pathogenic variant carriers would be told there is little or no advanta…

Then it is better to go for modern gene therapy and modify #BRCA genes than to subject millions of women to an prophylactic operation in which the risks are nevertheless not reduced to zero and automatically lead to mental problems. #GeneTherapy #mastectom

RT @LguzzardiM: UK Researchers explore why unaffected female #BRCA2 pathogenic variant carriers would be told there is little or no advanta…

RT @LguzzardiM: UK Researchers explore why unaffected female #BRCA2 pathogenic variant carriers would be told there is little or no advanta…

RT @LguzzardiM: UK Researchers explore why unaffected female #BRCA2 pathogenic variant carriers would be told there is little or no advanta…

RT @LguzzardiM: UK Researchers explore why unaffected female #BRCA2 pathogenic variant carriers would be told there is little or no advanta…

UK Researchers explore why unaffected female #BRCA2 pathogenic variant carriers would be told there is little or no advantage from risk reducing mastectomy? #readbetweenthelines #FactsMatter #genetics #patientsafety #bcsm #hereditarycancer https://t.co/